We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
The combined treatment with ketogenic diet and metformin slows tumor growth in two mouse models of triple negative breast cancer.
- Authors
Schmidt, Karen; Thatcher, Amber; Grobe, Albert; Broussard, Pamela; Hicks, Linda; Gu, Haiwei; Ellies, Lesley G; Sears, Dorothy D.; Kalachev, Leonid; Kroll, Eugene
- Abstract
Background: Many tumors contain hypoxic microenvironments caused by inefficient tumor vascularization. Hypoxic tumors have been shown to resist conventional cancer therapies. Hypoxic cancer cells rely on glucose to meet their energetic and anabolic needs to fuel uncontrolled proliferation and metastasis. This glucose dependency is linked to a metabolic shift in response to hypoxic conditions. Methods: To leverage the glucose dependency of hypoxic tumor cells, we assessed the effects of a mild reduction in systemic glucose by controlling both dietary carbohydrates with a ketogenic diet and endogenous glucose production by using metformin on two mouse models of triple-negative breast cancer (TNBC). Results: Here, we showed that animals with TNBC treated with the combination regimen of ketogenic diet and metformin (a) had their tumor burden lowered by two-thirds, (b) displayed 38% slower tumor growth, and (c) showed 36% longer latency, compared to the animals treated with a ketogenic diet or metformin alone. As a result, lowering systemic glucose by this combined dietary and pharmacologic approach improved overall survival in our mouse TNBC models by 31 days, approximately equivalent to 3 years of life extension in human terms. Conclusion: This preclinical study demonstrates that reducing systemic glucose by combining a ketogenic diet and metformin significantly inhibits tumor proliferation and increases overall survival. Our findings suggest a possible treatment for a broad range of hypoxic and glycolytic tumor types that can augment existing treatment options to improve patient outcomes.
- Subjects
BREAST cancer prognosis; BREAST tumor treatment; METFORMIN; BIOLOGICAL models; GLUCOSE; KETOGENIC diet; RESEARCH funding; BREAST tumors; TREATMENT effectiveness; CANCER patients; MANN Whitney U Test; DESCRIPTIVE statistics; CELL lines; MICE; METASTASIS; COMBINED modality therapy; ANIMAL experimentation; DIETARY carbohydrates; HYPOXEMIA
- Publication
Translational Medicine Communications, 2024, Vol 9, Issue 1, p1
- ISSN
2396-832X
- Publication type
Article
- DOI
10.1186/s41231-024-00178-8